News
![EGS Beteiligungen AG exercises right to convert bond and increases its shareholding in Siegfried to 6.2% registered shares](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
EGS Beteiligungen AG exercises right to convert bond and increases its shareholding in Siegfried to 6.2% registered shares
EGS Beteiligungen AG exercises right to convert bond and increases its shareholding in Siegfried to 6.2% registered shares
![Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering
Siegfried to acquire an early-phase CDMO in Wisconsin (US) to strengthen its Drug Substances service offering
![Annual General Shareholders’ Meeting 2024:
Sonova shareholders approve all motions of the Board of Directors](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Annual General Shareholders’ Meeting 2024: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2024:
Sonova shareholders approve all motions of the Board of Directors
![Relief Therapeutics Announces Executive Changes](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Relief Therapeutics Announces Executive Changes
Relief Therapeutics Announces Executive Changes
![Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
![Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis
Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis
![Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
![Financial year 2023/24: Sonova ends year on improving trajectory after growth picks up in second half](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Financial year 2023/24: Sonova ends year on improving trajectory after growth picks up in second half
Financial year 2023/24: Sonova ends year on improving trajectory after growth picks up in second half
![Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
![Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives
![Sonova announces Management Board succession](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Sonova announces Management Board succession
Sonova announces Management Board succession
![Relief Therapeutics has published its Annual Report](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Relief Therapeutics has published its Annual Report
Relief Therapeutics has published its Annual Report
![RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
![EQS-Adhoc: BB Biotech AG publishes its interim report](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
![EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
![Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales
![Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
![Annual General Meeting of Kuros Biosciences approves all resolutions](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Annual General Meeting of Kuros Biosciences approves all resolutions
Annual General Meeting of Kuros Biosciences approves all resolutions
![Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected
Shareholders of Evolva Holding SA in liquidation approve BoD proposals at AGM; revocation of liquidation and delisting also approved whereas introduction of opting-out was rejected
![Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
![Lonza Appoints Wolfgang Wienand as New Chief Executive Officer](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
![RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
![Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules
Approval of temporary exemption from certain conditions for maintaining listing pursuant to art. 7 Listing Rules
![Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g
Evolva Holding in liquidation SA publishes liquidation interim financial statements and agenda for 2024 annual general meeting; reports positive purchase price adjustment of CHF 1,929,000 under SPA; g
![Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE